Document Detail


Predicting which children are at risk for ependymoma relapse.
MedLine Citation:
PMID:  16575538     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Ependymomas account for 6-12% of all pediatric intracranial tumors. Despite complete resection and radiation, about 50% of patients relapse and have subsequent dismal prognoses. As no clinical findings reliably forecast tumor recurrence, we sought to determine if gene expression profiling could be used to distinguish patients at high risk for relapse at initial diagnosis, and thereby make them candidates for innovative treatments at an early stage. We extracted RNA from 13 ependymoma specimens: 7 from patients who experienced tumor recurrence, and 6 from patients who have not recurred. RNA was applied to Affymetrix HG-U133 plus 2.0 microarray chips, and microarrays were analyzed with GeneSpring 7.0 and Prediction Analysis of Microarrays (PAM) software. The 3-gene subset of PLEK (pleckstrin), NF-kappaB2 (nuclear factor kappa beta-2), and LOC374491 (TPTE and PTEN homologous inositol phosphatase pseudogene) was identified as the minimal subset capable of accurately distinguishing tumors according to recurrence. In summary, gene expression profiling may be valuable, perhaps in combination with clinical findings identified in some studies, for identifying children at high risk for ependymoma relapse.
Authors:
Kristina Sowar; Jennifer Straessle; Andrew M Donson; Michael Handler; Nicholas K Foreman
Related Documents :
9014688 - Decreased e-cadherin expression is associated with haematogenous recurrence and poor pr...
11489828 - Expression of x-linked inhibitor of apoptosis as a novel prognostic marker in radically...
19834398 - The correlation and prognostic significance of mgmt promoter methylation and mgmt prote...
12652618 - Expression of the lipogenic enzyme fatty acid synthase (fas) as a predictor of poor out...
10837938 - Prognostic factors for medulloblastoma.
22698478 - Assessment of cancer control outcomes in patients with high-risk renal cell carcinoma t...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2006-03-31
Journal Detail:
Title:  Journal of neuro-oncology     Volume:  78     ISSN:  0167-594X     ISO Abbreviation:  J. Neurooncol.     Publication Date:  2006 May 
Date Detail:
Created Date:  2006-05-23     Completed Date:  2006-08-22     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8309335     Medline TA:  J Neurooncol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  41-6     Citation Subset:  IM    
Affiliation:
University of Colorado at Denver and Health Sciences Center (UCDHSC) and Denver Children's Hospital, Denver, Colorado 80045, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Brain Neoplasms / classification,  genetics*,  pathology*
Child
Child, Preschool
Ependymoma / classification,  genetics*,  pathology*
Gene Expression Profiling
Humans
Neoplasm Recurrence, Local / pathology*
Oligonucleotide Array Sequence Analysis
Prognosis
RNA, Messenger / analysis
Retrospective Studies
Reverse Transcriptase Polymerase Chain Reaction
Risk Factors
Grant Support
ID/Acronym/Agency:
R25 CA49981/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/RNA, Messenger

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Somnolence syndrome after focal radiation therapy to the pineal region: case report and review of th...
Next Document:  Treatment recommendations for the various subgroups of neurocytomas.